MCL1 and plasma cell myeloma: In response to ABC294640, a dual dihydroceramide desaturase and SPHK2 inhibitor, loss-of-myeloma cell viability was associated with degradation of c-Myc and Mcl-1, similar to the phenotype observed by Wallington-Beddoe et al. in ALL22.